JT
Jonathan Tobin
Non Executive Director at Adendra Therapeutics
London, England
Overview
Jonathan Tobin is a Partner at Brandon Capital in London, with a strong background in drug discovery, genetics, and venture capital. He has made significant investments in companies like CatalYm, Myricx Bio, and Pheon Therapeutics, showcasing his expertise in the pharmaceutical industry and business strategy.
Tobin's career highlights include serving as a Non-Executive Director at multiple biotechnology companies and being a member of the Investment Advisory Committee for KHAN Technology Transfer Fund I, demonstrating his strategic leadership and contribution to the growth of innovative startups in the life sciences sector.
Work Experience
Partner
2021 - Current
I'm focused on leading investments in biotech companies globally. jtobin@bcpvc.com
Investor-in-Residence
2023
As investor-in-residence I am advising the CRH Seed fund team on their early stage investments in start-ups based on the ground breaking research emerging from Cancer Research UK laboratories.
Non Executive Director
2024
Non-exec director representing Cancer Research Horizons
Non Executive Director
2023
Non Executive Director
2021
Non Executive Director
2022
First-in-class anti-GDF15 mAb in Phase 2 in solid tumour patients
Non Executive Director
2022
Non Executive Director
2022
Member of the Investment Advisory Committee
2020
KHAN-I is a new fund backed by the Max Planck Foundation, European Investment Fund, and Austrian government to back early stage drug discovery projects originating from Germany and Austria to create new biotech opportunities.
Commercial Partnerships Advisor
2021 - 2021
Large consultancy project advising Genomics England on part of their commercial strategy